WeVote
Log In

Bill

Bill

SR 129

A resolution to recognize June 9, 2026, as Focal Segmental Glomerulosclerosis (FSGS) Day.

2025-2026 Regular Session Introduced by Kevin Hertel and 1 co-sponsor

Designates June 9, 2026 as FSGS Day in Michigan to raise awareness, support patients, and promote better diagnosis, care access, and research for the kidney disease.

ADOPTED
0
WeVote Research Nonpartisan
Bill Summary · SR 129

Overview

  • Bill: SR 129 (Michigan Senate)
  • Type: State Senate Resolution
  • Session: 2025-2026
  • Sponsor: Senator Kevin Hertel (co-sponsor)
  • Date Introduced: June 10, 2026
  • Purpose: Recognize June 9, 2026 as Focal Segmental Glomerulosclerosis (FSGS) Day

Purpose and Intent

  • The resolution designates a specific day, June 9, 2026, as FSGS Day in Michigan.
  • Goals of the designation:
    • Raise awareness of FSGS, a rare kidney disease.
    • Provide support and inspiration to patients and families affected by FSGS.
    • Promote efforts to improve diagnosis, access to care, and future treatments.

Key Provisions

  • Establishes June 9, 2026, as FSGS Day within the state.
  • Encourages awareness activities, patient support, and advocacy related to FSGS.
  • Signals support for improved diagnosis, access to nephrology care, and progression of research and therapies for FSGS.

Who/What Is Affected

  • Primary: Michigan residents, particularly:
    • Individuals diagnosed with FSGS or at risk for rare kidney diseases.
    • Families and caregivers of FSGS patients.
    • Healthcare providers, patient advocacy groups (e.g., NephCure), researchers, and policymakers focusing on kidney disease.
  • Indirectly affects:
    • State health systems and funding priorities by highlighting the burden of FSGS.
    • Public awareness and education efforts related to kidney disease.

Procedural and Timeline Aspects

  • The resolution is a commemorative, non-binding measure acknowledging the day.
  • No fiscal appropriations or regulatory changes are attached to the resolution.
  • Effective date: As soon as enacted by the Senate (no specific date beyond introduction/approval timeline).
  • Related context included in the resolution emphasizes:
    • The burden of chronic kidney disease and FSGS on patients and the healthcare system.
    • The disproportionate impact on Black communities due to higher-risk APOL1 gene variants.
    • Ongoing clinical trials and the potential for new therapies and improved diagnostics.

Context and Relevance

  • Highlights FSGS as a significant contributor to kidney disease burden, including high rates of progression to dialysis or transplant.
  • Emphasizes disparities in incidence and outcomes, particularly among people of African ancestry.
  • Aligns with broader efforts to promote early detection, specialized nephrology care, and accelerated development of treatments for rare kidney diseases.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.